Prostate-specific antigen to predict outcome of external beam radiation for prostate cancer: walter reed army medical center experience 1988–1995
- 1 January 1999
- Vol. 53 (1), 131-138
- https://doi.org/10.1016/s0090-4295(98)00464-6
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- External beam radiotherapy for stage T1/T2 prostate cancer: how does it stack up?Urology, 1998
- Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and GoserelinNew England Journal of Medicine, 1997
- Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level ≤ 10 ng/ml: Radiation therapy or surgery?International Journal of Radiation Oncology*Biology*Physics, 1997
- Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional updatePublished by American Medical Association (AMA) ,1997
- Time to second prostate-specific antigen failure is a surrogate endpoint for prostate cancer death in a prospective trial of therapy for localized diseaseUrology, 1996
- 2 Conformal technique dose escalation in prostate cancer: improved cancer control with higher doses in patients with pretreatment PSA 10 ngm/mlInternational Journal of Radiation Oncology*Biology*Physics, 1995
- Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: Prognostic implicationsInternational Journal of Radiation Oncology*Biology*Physics, 1994
- PSA confirmation of cure at 10 years of T1B, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiationInternational Journal of Radiation Oncology*Biology*Physics, 1994
- The TNM classification of prostate cancerThe Prostate, 1992
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958